Clinical Trial: Pembrolizumab for Advanced NSCLC and PS 2-3
Study Status: Completed
Recruit Status: RECRUITING
Condition: Non-Small Cell Lung Cancer (NSCLC)
Study Type: INTERVENTIONAL
Official Title: A Phase II Study of the Effects of Pembrolizumab on Quality of Life for Patients With Treatment-Naïve, Advanced or Metastatic NSCLC and Poor Performance Status
Brief Summary:
This single center open-label trial will enroll a single cohort of patients with advanced non-small cell lung cancer (NSCLC) who are ineligible for treatment with curative intent due to 1) disease stage IV, or 2) inability to tolerate intensive surgery or chemo-radiation.Patients will be eligible for the trial if ISMMS reviewed samples from tumor biopsy have a PDL-1 TPS ? 1% and have ECOG performance status rated 2 or 3.All patients will receive anti PD-1 therapy with pembrolizumab 200mg IV every 3 weeks, during…
Read more